IL-31 Reporter HEK 293 Cells

Product Unit size Cat. code Docs. Qty. Price

HEK-Blue™ IL-31 Cells

Human IL-31 Reporter Cells

Show product

3-7 x 10e6 cells


HEK-Blue™ IL-31 cells signaling pathway
HEK-Blue™ IL-31 cells signaling pathway

Interleukin-31 Reporter Cells

HEK-Blue™ IL-31 cells were engineered from the human embryonic kidney HEK 293 cell line to detect bioactive interleukin-31 (IL-31) by monitoring the activation of the JAK/STAT5 pathway. IL-31 is a secreted cytokine that seems to be strongly involved in chronic inflammation in different skin diseases, including atopic dermatitis and allergic contact dermatitis [1].

More details More details


Cell line description

HEK-Blue™ IL-31 cells were generated by stable overexpression of the genes encoding for the human IL-31Rα and human OSMRβ (oncostatin M receptor β), human STAT5b, and a STAT5-inducible secreted embryonic alkaline phosphatase (SEAP) reporter. STAT5-dependent SEAP activity is readily assessable in the supernatant using QUANTI-Blue™ Solution, a detection reagent. HEK-Blue™ IL-31 cells detect human IL-31 but not murine IL-31 (see figures). Of note, they also respond to human type II interferon (IFN-γ; see figures). However, they do not respond to human type I IFNs (IFN-α/IFN-β; see figures).

Features of HEK-Blue™ IL-31 cells

  • Fully functional IL-31 signaling pathway
  • Readily assessable STAT5-inducible SEAP reporter activity

Applications of HEK-Blue™ IL-31 cells

  • Detection of human IL-31 (1 pg/ml - 1 ng/ml)
  • Screening of anti-IL-31 and anti-IL-31 receptor antibodies



1. Datsi A, et al., 2021. Interleukin-31: The "itchy" cytokine in inflammation and therapy. Allergy. 76: 2982-2997.


Validation of IL-31Rα and OSMRβ expression
Validation of IL-31Rα and OSMRβ expression

Validation of the expression of human IL-31 receptor chains by HEK-Blue™ IL-31 cells. 5 x 105 cells were incubated with either a (A) PE-conjugated isotype control (blue) or a PE-conjugated Anti-hIL-31Rα mAb (red), or (B) APC-conjugated isotype control (blue) or a APC-conjugated Anti-hOSMR mAb (red) for 30 minutes. The binding affinity was then measured using flow cytometry.

Cellular response to IL-31
Cellular response to IL-31

Dose-response of HEK-Blue™ IL-31 cells to recombinant IL-31. Cells were stimulated with increasing concentrations of recombinant human IL-31 (hIL-31) and murine IL-31 (mIL-31). After overnight incubation, the STAT5 response was determined using QUANTI‑Blue™ Solution, a SEAP detection reagent. The optical density (OD) at 630 nm is shown as mean ± SEM.

IL-31 signaling inhibition
IL-31 signaling inhibition

Dose-dependent inhibition of HEK‑Blue™ IL-31 cellular response using a neutralizing antibody against IL-31Rα. An increasing concentration of a neutralizing anti-IL-31RA antibody was incubated with HEK‑Blue™ IL-31 cells for 3 hours before the addition of recombinant human IL-31 (0.03 ng/ml). After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™. Data are shown as a percentage (%) of activity.

Cell line specificity
Cell line specificity

Response of HEK-Blue™ IL-31 cells to a panel of cytokines. Cells were stimulated with various human and murine recombinant cytokines: 1 ng/ml of hIL-31, 100 ng/ml mIL-31, 10 ng/ml hIL-6, 100 ng/ml hIL-11, IL-27, hIFN-γ, and 1000 U/ml hIFN-α or IFN-β. After overnight incubation, SEAP activity was assessed using QUANTI‑Blue™. The OD at 630 nm is shown as mean ± SEM.

Back to the top


Antibiotic resistance: Blasticidin, Hygromycin, and  Zeocin®

Growth medium: DMEM, 4.5 g/l glucose, 2-4 mM L-glutamine, 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™

Specificity: human IL-31

Detection range: 1 pg/ml - 1 ng/ml

Quality Control:

  • The STAT5-dependent SEAP reporter activity in response to human IL-31 is validated.
  • The expression of human IL-31Rα and OSMRβ is confirmed by flow cytometry.
  • The stability for 20 passages, following thawing, is verified. 
  • These cells are guaranteed mycoplasma-free. 

This product is covered by a Limited Use License (See Terms and Conditions).

Back to the top


Shipped on dry ice Shipped on dry ice (Europe, USA, Canada, and some areas in Asia)

Back to the top


The cytokine interleukin 31 (IL-31) belongs to the Type I/II cytokine receptor family, and more specifically to the IL-6/gp130 family. IL-31 signals through a heterodimeric receptor comprised of the gp130-like subunit IL-31Rα and the OSMRb (oncostatin M receptor) subunit. The binding of IL-31 to its receptor triggers activation of the JAK/STAT, Akt/PI3K, and MAPK signaling pathways [1,2]. IL-31 receptor complex is expressed in epithelial, neuronal as well as immune cells. Little is known about the physiological function of IL-31. It is mainly secreted by IL-4-activated T cells, thereby contributing to Th2-weighted inflammation [1,2]. Several reports indicate that IL-31 is implicated in disorders such as atopic dermatitis, asthma, and inflammatory bowel disease [1,2]. Of note, IL-31 appears a critical cytokine involved in neuro-immune communication, through the mediation of inflammatory itch [1,2]. Targeting the IL-31 pathway is a promising therapeutic option for dermatologic and non-dermatologic diseases with enhanced IL-31 expression [1,2].



1. Bagci I.S. and Ruzicka, T., 2018. IL-31: A new player in dermatology and beyond. J. Allergy Clin Immunol. 141(3):858-866.
2. Datsi A., et al., 2021. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 76:2982-97.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top

Notification:  This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

Customer Service
& Technical Support
Shopping cart is empty